# The NOR-SWITCH Study

> **NCT02148640** · PHASE4 · COMPLETED · sponsor: **Diakonhjemmet Hospital** · enrollment: 482 (actual)

## Conditions studied

- Rheumatoid Arthritis
- Spondyloarthritis
- Psoriatic Arthritis
- Ulcerative Colitis
- Crohn's Disease
- Psoriasis Chronic

## Interventions

- **DRUG:** Innovator infliximab
- **DRUG:** Biosimilar infliximab

## Key facts

- **NCT ID:** NCT02148640
- **Lead sponsor:** Diakonhjemmet Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2016-06
- **Final completion:** 2017-01
- **Target enrollment:** 482 (ACTUAL)
- **Last updated:** 2017-09-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02148640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02148640, "The NOR-SWITCH Study". Retrieved via MORVS 2026-10-09 from https://api.morvs.ai/clinical/NCT02148640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*